ERBB2 and breast neoplasm: The humanized recombinant monoclonal antibody trastuzumab (HerceptinTM) was the first anti-Her2 agent approved by the US Food and Drug Administration in 1998 for the treatment of Her2-positive breast tumors [20, 21].